C. Stober

发表

Optimizing vascular access for patients receiving intravenous systemic therapy for early-stage breast cancer-a survey of oncology nurses and physicians.

M. Clemons, D. Fergusson, S. Mcdiarmid, 2018, Current oncology.

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review

B. Gyawali, B. Hutton, M. Clemons, 2017, Journal of global oncology.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study

G. Pond, S. Damaraju, B. Hutton, 2018, Supportive Care in Cancer.

Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

G. Pond, B. Hutton, M. Clemons, 2021, Journal of bone oncology.

Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients

J. Caudrelier, B. Hutton, M. Clemons, 2019, Clinical breast cancer.

Perceptions of vascular access for intravenous systemic therapy and risk factors for lymphedema in early-stage breast cancer-a patient survey.

M. Clemons, S. Gertler, D. Fergusson, 2018, Current oncology.

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review.

J. Caudrelier, B. Hutton, M. Clemons, 2018, Cancer treatment reviews.

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)

B. Hutton, M. Clemons, D. Fergusson, 2018, PloS one.

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel–cyclophosphamide chemotherapy for breast cancer: a systematic review

B. Hutton, M. Clemons, D. Fergusson, 2016, Breast Cancer Research and Treatment.

Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers

M. Clemons, L. Vandermeer, Mashari Alzahrani, 2022, Supportive Care in Cancer.

Comparison of two care schedules for monitoring of cardiotoxicity in patients receiving trastuzumab-based therapy for early-stage breast cancer: study protocol for a randomized controlled non-inferiority trial

M. Clemons, D. Fergusson, S. Dent, 2017 .

Oral magnesium supplements for cancer treatment‐induced hypomagnesemia: Results from a pilot randomized trial

B. Hutton, M. Clemons, D. Fergusson, 2021, Health science reports.

A Randomized Trial Comparing 3- versus 4-Monthly Cardiac Monitoring in Patients Receiving Trastuzumab-Based Chemotherapy for Early Breast Cancer

G. Pond, B. Hutton, M. Clemons, 2021, Current oncology.

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

G. Pond, B. Hutton, M. Clemons, 2020, European Journal of Cancer.

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer

G. Pond, B. Hutton, M. Clemons, 2020, Journal of bone oncology.

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer

G. Pond, M. Clemons, K. Thavorn, 2021, Current oncology.

A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy

B. Hutton, M. Clemons, D. Fergusson, 2019, Breast Cancer Research and Treatment.

Creating a pragmatic trials program for breast cancer patients: Rethinking Clinical Trials (REaCT)

B. Hutton, M. Clemons, K. Thavorn, 2019, Breast Cancer Research and Treatment.

A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.

G. Pond, M. Clemons, D. Fergusson, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Is This Conference for Real? Navigating Presumed Predatory Conference Invitations.

D. Moher, B. Hutton, M. Clemons, 2017, Journal of oncology practice.

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer—a survey of physicians and patients

B. Hutton, M. Clemons, D. Fergusson, 2018, Supportive Care in Cancer.

The COVID-19 pandemic: An opportunity to rethink and harmonise the frequency of follow-up visits for patients with early stage breast cancer

B. Hutton, M. Clemons, A. Arnaout, 2021, Cancer Treatment Reviews.

Optimising weight-loss interventions in cancer patients—A systematic review and network meta-analysis

L. Jones, W. Cheng, B. Hutton, 2021, PloS one.

Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review

B. Hutton, M. Clemons, D. Fergusson, 2018, Breast cancer research and treatment.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)

B. Hutton, M. Clemons, D. Fergusson, 2018, Supportive Care in Cancer.

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer

B. Hutton, M. Clemons, S. Gertler, 2018, Breast Cancer Research and Treatment.

A randomized trial comparing vascular access strategies for patients receiving chemotherapy with trastuzumab for early-stage breast cancer

B. Hutton, M. Clemons, D. Fergusson, 2020, Supportive Care in Cancer.

De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

B. Hutton, M. Clemons, D. Fergusson, 2019, Breast Cancer Research and Treatment.

Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review

B. Hutton, M. Clemons, L. Vandermeer, 2020, Supportive Care in Cancer.

Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information.

G. Pond, Z. Kos, M. Clemons, 2020, Clinical breast cancer.

A Randomized Controlled Trial Comparing Alloderm-RTU with DermACELL in Immediate Subpectoral Implant-Based Breast Reconstruction

G. Pond, B. Hutton, M. Clemons, 2020, Current oncology.

Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial

Z. Kos, B. Hutton, M. Clemons, 2019, Journal of evaluation in clinical practice.

Predatory Invitations from Journals: More Than Just a Nuisance?

Brian Hutton, Mark Clemons, Anil Abraham Joy, 2017, The oncologist.

Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer.

M. Clemons, K. Thavorn, D. Fergusson, 2020, Journal of evaluation in clinical practice.

A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.

B. Hutton, C. Canil, D. Fergusson, 2019, Journal of Clinical Oncology.

A randomized clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy

G. Pond, B. Hutton, M. Clemons, 2020, Supportive Care in Cancer.

Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.

L. Vandermeer, C. Stober, M. Clemons, 2024, Breast cancer research and treatment.

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer

G. Pond, D. Cella, M. Clemons, 2023, Current oncology.